Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers
Qiu Rao(Indiana University School of Medicine), Liang Cheng(University of North Carolina at Chapel Hill), Robert E. Emerson(Indiana University – Purdue University Indianapolis), David J. Grignon(Indiana University School of Medicine), Antonio López-Beltrán(Cordoba University), Muhammad T. Idrees(Indiana University School of Medicine), Rodolfo Montironi(Marche Polytechnic University), John N. Eble(Indiana University School of Medicine), Michael O. Koch, Lee Ann Baldridge(Indiana University School of Medicine), Xiao-jun Zhou(Nanjing University), Wenbin Huang(Nanjing Medical University), Shaobo Zhang(Indiana University – Purdue University Indianapolis), Sean R. Williamson(Wayne State University)
Cited by 100
Related Papers
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
|Modern Pathology|2017|404
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
|Cancers|2021|289
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
|Cells|2020|256
The World Health Organization 2016 classification of testicular non‐germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel
|Histopathology|2016|236
Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs
|Journal of Clinical Investigation|2016|175